.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
EXPAND was a landmark phase 3 trial because few disease-modifying therapies had previously demonstrated an effect on disability progression in secondary progressive multiple sclerosis. The double-blind randomized study compared once-daily siponimod with placebo in people with SPMS. Siponimod significantly reduced the risk of three-month confirmed disability progression and also reduced relapse activity and MRI measures of inflammation and brain volume loss. The benefit was particularly relevant in patients with evidence of ongoing inflammatory activity, helping establish the idea that selected SPMS patients can still benefit from disease-modifying therapy. For HCPs, the practical implication is that the transition from relapsing MS to progressive disease should not automatically end consideration of active treatment. Disease phenotype matters. Patients with recent relapses or MRI activity may have more to gain than patients with purely non-inflammatory progression. Siponimod also requires appropriate safety screening and CYP2C9 genotype assessment. The trial is directly relevant to IANCON's interest in modern MS treatment and the distinction between inflammatory activity and progression.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
EXPAND was a landmark phase 3 trial because few disease-modifying therapies had previously demonstrated an effect on disability progression in secondary progressive multiple sclerosis. The double-blind randomized study compared once-daily siponimod with placebo in people with SPMS. Siponimod significantly reduced the risk of three-month confirmed disability progression and also reduced relapse activity and MRI measures of inflammation and brain volume loss. The benefit was particularly relevant in patients with evidence of ongoing inflammatory activity, helping establish the idea that selected SPMS patients can still benefit from disease-modifying therapy. For HCPs, the practical implication is that the transition from relapsing MS to progressive disease should not automatically end consideration of active treatment. Disease phenotype matters. Patients with recent relapses or MRI activity may have more to gain than patients with purely non-inflammatory progression. Siponimod also requires appropriate safety screening and CYP2C9 genotype assessment. The trial is directly relevant to IANCON's interest in modern MS treatment and the distinction between inflammatory activity and progression.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
